输注含重组载脂蛋白A-I Milano的高密度脂蛋白模拟物对急性冠脉综合征患者冠状动脉疾病的影响:MILANO-PILOT随机临床试验
这项双盲随机试验在加拿大和欧洲22家医院比较了每周静脉输注MDCO-216(20 mg/kg,n=59)与安慰剂(n=67)对接受他汀治疗的急性冠脉综合征患者冠状动脉粥样硬化进展的影响。主要终点为基线至第36天百分粥样斑块体积(PAV)的标称变化,通过系列血管内超声测量。结果显示MDCO-216未产生增量斑块消退(PAV差异0.73%,95%CI -0.07至1.52,P=0.07)。
要点
- 在当代他汀治疗背景下,输注MDCO-216未显著改善PAV变化(差异0.73%,P=0.07)。
- 两组斑块消退患者比例相似(PAV消退67.2% vs 55.8%,P=0.21)。
核心结论
- 在急性冠脉综合征患者中,当代他汀治疗背景下输注MDCO-216未产生增量斑块消退。
研究设计与样本
- 双盲、随机临床试验,在加拿大和欧洲22家医院进行。
- 比较5次每周静脉输注MDCO-216 20 mg/kg(n=59)与安慰剂(n=67)在急性冠脉综合征且接受他汀治疗的患者中的效果。
- 共122例随机患者,平均(SD)年龄61.8(10.4)岁,93例男性(76.2%),61例(50.0%)有既往他汀使用史,平均(SD)低密度脂蛋白胆固醇水平87.6(40.5)mg/dL。
- 113例(92.6%)在随访时有可评估的影像学结果。
主要发现
- 经基线值调整的百分粥样斑块体积在安慰剂组降低0.94%,MDCO-216组降低0.21%(差异0.73%;95%CI -0.07至1.52;P=0.07)。
临床怎么用
- 对于急性冠脉综合征且接受当代他汀治疗的患者,输注MDCO-216未显示额外斑块消退获益。
- MDCO-216输注导致高密度脂蛋白胆固醇水平降低,需关注其安全性影响。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
IMPORTANCE: Infusing a high-density lipoprotein mimetic containing apolipoprotein A-I Milano demonstrated potential atheroma regression in patients following an acute coronary syndrome. To our knowledge, the effect of infusing a new mimetic preparation (MDCO-216) with contemporary statin therapy is unknown. OBJECTIVE: To determine the effect of infusing MDCO-216 on coronary atherosclerosis progression. DESIGN, SETTING, AND PARTICIPANTS: This double-blind, randomized clinical trial conducted in 22 hospitals in Canada and Europe compared the effects of 5 weekly intravenous infusions of MDCO-216 at a dose of 20 mg/kg weekly (n = 59) with placebo (n = 67) in statin-treated patients with an acute coronary syndrome. MAIN OUTCOMES AND MEASURES: The primary efficacy measure was the nominal change in percent atheroma volume (PAV) from baseline to day 36 as measured by serial intravascular ultrasonography. The secondary efficacy measures were the nominal changes in normalized total atheroma volume (TAV), atheroma volume in the most diseased 10-mm segment, and the percentage of patients who demonstrated plaque regression. Safety and tolerability were also evaluated. RESULTS: Among 122 randomized patients (mean [SD] age, 61.8 [10.4] years; 93 men [76.2%]; 61 [50.0%] with prior statin use; and a mean [SD] low-density lipoprotein cholesterol [LDL-C] level of 87.6 [40.5] mg/dL [to convert to millimoles per liter, multiply by 0.0259]), 113 (92.6%) had evaluable imaging results at follow-up. The receiving-treatment LDL-C levels were comparable with the placebo and MDCO-216 (68.6 vs 70.5 mg/dL; difference, -2.5 mg/dL; 95% CI, -10.1 to 5.0; P = .51). A reduction in high-density lipoprotein cholesterol levels was observed in MDCO, but not placebo patients (-3.3 vs 3.0 mg/dL [to convert to millimoles per liter, multiply by 0.0259]; difference, -6.3 mg/dL; 95% CI, -8.5 to -4.1; P < .001). Percent atheroma volume, which was adjusted for baseline values, decreased 0.94% with the placebo and 0.21% with MDCO-216 (difference, 0.73%; 95% CI, -0.07 to 1.52; P = .07). Normalized TAV decreased 7.9 mm3 with the placebo and 6.4 mm3 with MDCO-216 (difference, 1.6 mm3; 95% CI, -5.6 to 8.7; P = .67), and atheroma volume in the most diseased segment decreased 1.8 mm3 with the placebo and 2.2 mm3 with MDCO-216 (difference 0.4 mm3; 95% CI, -4.4 to 3.5; P = .83). A similar percentage of patients demonstrated a regression of PAV (67.2% vs 55.8%; P = .21) and TAV (68.9% vs 71.2%; P = .79) in the placebo and MDCO-216 groups, respectively. CONCLUSIONS AND RELEVANCE: Among patients with an acute coronary syndrome, infusing MDCO-216 did not produce an incremental plaque regression in the setting of contemporary statin therapy. TRIAL REGISTRATION: ClinicalTrials.gov Identifier: NCT02678923.
引用
- Nicholls SJ, Puri R, Ballantyne CM, et al. Effect of Infusion of High-Density Lipoprotein Mimetic Containing Recombinant Apolipoprotein A-I Milano on Coronary Disease in Patients With an Acute Coronary Syndrome in the MILANO-PILOT Trial: A Randomized Clinical Trial. JAMA Cardiol. 2018. PMID: 30046837. doi:10.1001/jamacardio.2018.2112
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。